^
Association details:
| Biomarker: | CDA underexpression + SLC29A1 underexpression |
|---|---|
| Cancer: | Pancreatic Cancer |
| Drug: | 5-fluorouracil (Thymidylate synthase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
Published date:
11/17/2021
Excerpt:
Gemcitabine or 5-fluorouracil (5-FU) based treatments can be selected for pancreatic cancer....Analysis of both CDA and hENT1 was possible with 277 patients...individuals with low CDA mRNA and low hENT1 protein do better with 5-FU: median survival 29.3 (95% CI = 21.9–41.9) months compared to survival of 18.3 (95% CI = 13.9–28.3) months with gemcitabine (Table 3).
DOI:
10.3390/cancers13225758
